The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial
Shojaei F, Erfanifar A, Kalbasi S, et al.
BMC Endocr Disord. 2025;25(1):52.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial
Cunningham JW, Chatur S, Claggett BL, et al.
JAMA Cardiol. 2025:e250016.
Leggi
Efficacy and safety of finerenone in type 2 diabetes: a pooled analysis of trials of heart failure and chronic kidney disease
Ostrominski JW, Claggett BL, Miao ZM, et al.
Diabetes Care. 2025:dc241873.
Leggi
Glucagon-like peptide-1 receptor agonists and risk for depression in older adults with type 2 diabetes: a target trial emulation study
Tang H, Lu Y, Donahoo WT, et al.
Ann Intern Med. Pub. online 25 Feb 2025.
Leggi
Differential treatment effects on β-cell function using model-based parameters in type 2 diabetes: results from the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)
Utzschneider KM, Tripputi M, Butera NM, et al.
Diabetes Care. 2025:dc242419.
Leggi
Association of normal range of urinary albumin-to-creatinine ratio with all-cause mortality among diabetic adults with preserved kidney function: National Health and Nutrition Examination Survey (NHANES) 2003-2018
Pang X, Dan W, Lin L
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Universal screening for hyperglycemia in early pregnancy and the risk of adverse pregnancy outcomes
Shen L, Zhang S, Wen J, et al.
BMC Pregnancy Childbirth. 2025;25(1):203.
Leggi
The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice
Berry SA, Liarakos AL, Koutroukas V, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Time in range-A new gold standard in type 2 diabetes research?
Goshrani A, Lin R, O’Neal D, Ekinci EI
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point-of-care glucose testing in a non-intensive care unit setting: a heterogeneity of treatment effect analysis
Olsen MT, Jensen SH, Rasmussen LM, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi